Abstract
Rapid estrogen actions are triggered after estrogens are bound to a variety of proteins in organelles other than the nucleus. Those include classic estrogen receptors ERα and ERβ, novel membrane proteins that behave as estrogen receptors such as GPR30, ion channels, and other ligand receptors. In pancreatic α and β-cells, estrogens binding to a non-classical membrane estrogen receptors at physiological concentrations regulate ion channels and [Ca2+]i signals, provoking important physiological responses. In β-cells, 17β- estradiol regulates KATP channel activity and glucose-induced [Ca2+]i oscillations, eliciting changes in insulin release and the activation of Ca2+-dependent transcription factors. In α-cells, 17β-estradiol abolishes low glucose-induced [Ca2+]i oscillations.
Infectious Disorders - Drug Targets
Title: Rapid Regulation of Pancreatic α- and β- Cell Signalling Systems by Estrogens
Volume: 8 Issue: 1
Author(s): Cristina Ripoll, Ana B. Ropero, Paloma Alonso-Magdalena, Ivan Quesada, Esther Fuentes and Angel Nadal
Affiliation:
Abstract: Rapid estrogen actions are triggered after estrogens are bound to a variety of proteins in organelles other than the nucleus. Those include classic estrogen receptors ERα and ERβ, novel membrane proteins that behave as estrogen receptors such as GPR30, ion channels, and other ligand receptors. In pancreatic α and β-cells, estrogens binding to a non-classical membrane estrogen receptors at physiological concentrations regulate ion channels and [Ca2+]i signals, provoking important physiological responses. In β-cells, 17β- estradiol regulates KATP channel activity and glucose-induced [Ca2+]i oscillations, eliciting changes in insulin release and the activation of Ca2+-dependent transcription factors. In α-cells, 17β-estradiol abolishes low glucose-induced [Ca2+]i oscillations.
Export Options
About this article
Cite this article as:
Ripoll Cristina, Ropero B. Ana, Alonso-Magdalena Paloma, Quesada Ivan, Fuentes Esther and Nadal Angel, Rapid Regulation of Pancreatic α- and β- Cell Signalling Systems by Estrogens, Infectious Disorders - Drug Targets 2008; 8 (1) . https://dx.doi.org/10.2174/187152608784139668
DOI https://dx.doi.org/10.2174/187152608784139668 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface: Conference Proceedings VII Immunonutrition Workshop “Eating for Preventing” [Carovigno, (Italy) May 1-3, 2014]-Second Part-
Endocrine, Metabolic & Immune Disorders - Drug Targets Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimers Disease
Current Neuropharmacology Technological Options for the Production of Health-Promoting Proteins and Peptides Derived from Milk and Colostrum
Current Pharmaceutical Design Endocrinological Aspects of Proteinuria and Podocytopathy in Diabetes: Role of the Aldosterone/Mineralocorticoid Receptor System
Current Diabetes Reviews Conference Report:
CNS & Neurological Disorders - Drug Targets Synergy of microRNA and Stem Cell: A Novel Therapeutic Approach for Diabetes Mellitus and Cardiovascular Diseases
Current Diabetes Reviews Cardioprotection by Regular Ethanol Consumption: Potential Mechanisms and Clinical Application
Current Drug Abuse Reviews Glucocorticoids: Structure, Signaling and Molecular Mechanisms in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema
Current Molecular Medicine Astrocyte Signaling and Multiple Sclerosis
Current Signal Transduction Therapy Determination of Sitagliptin with Fluorescamine in Tablets and Spiked Serum Samples by Spectrofluorimetry and a Degradation Study
Current Pharmaceutical Analysis Treatment of Estrogen Receptor-Positive Breast Cancer
Current Medicinal Chemistry Combination of Daidzein, Hemin and Bms182874 Halts the Progression of Diabetes-Induced Experimental Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Oxidant Gene Therapy by NFkB Decoy Oligodeoxynucleotide
Current Pharmaceutical Biotechnology Biomarkers of Diabetic Nephropathy, the Present and the Future
Current Diabetes Reviews Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Molecular Targets for Promoting Wound Healing in Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Applications of Mesenchymal Stem Cells in Cartilage Tissue Engineering- Part 1
Recent Patents on Regenerative Medicine Classification, Biotransformation and Antioxidant Activity of Olive Fruit Biophenols: A Review
Current Bioactive Compounds Determinants of Increased Cardiovascular Disease in Obesity and Metabolic Syndrome
Current Medicinal Chemistry Discovery of 6-Deoxydapagliflozin as a Highly Potent Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Medicinal Chemistry